JMP Securities, in a new report, writes that the promising mechanistic and clinical activity for Roche’s drug candidate, RG6292, should support advancement of iBio’s (NYSEA:IBIO) IBIO-101.
IBIO-101 is an anti-CD25 antibody designed to selectively bind and deplete Tregs in the tumor microenvironment without compromising immunostimulatory interleukin 2 signaling to other T-cells, thereby generating strong anti-tumor responses.
Analyst Roy Buchanan, Ph.D., said two abstracts for Roche’s anti-CD25, Teff-sparing, afucosylated monoclonal antibody, RG6292, presented at AACR from the Phase 1 trials in solid tumors, support the purported mechanistic rationale and provide initial signals of clinical efficacy.
The abstracts are available here and here.
Roche intends additional development of RG6292 and this should “support optimism that there may be value in IBIO-101, iBio’s afucosylated anti-CD25 monoclonal antibody,” Dr. Buchanan said.
